Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments

References

• Salfeld J, Kaymakçalan Z, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum 1998; 41:S57.
   Web of Science ®Google Scholar
• AbbVie Corporation, St-Laurent QC. Humira (adalimumab): Product monograph; 2015 Nov 15 [accessed 2016 Oct 19]. http://www.abbvie.ca/content/dam/abbviecorp/ca/english/docs/HUMIRA_PM_EN.pdf.
   Google Scholar
• Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30(16):1443-53; PMID:8232330; http://dx.doi.org/10.1016/0161-5890(93)90106-L
   PubMed Web of Science ®Google Scholar
• Janssen Inc., Toronto, Ontario. Remicade (infliximab): Product monograph; 2015 Jul 22 [accessed 2016 Oct 19]. https://www.janssen.com/canada/sites/www_janssen_com_canada/files/product/pdf/rmc07222015cpm_nc_183500.pdf.
   Google Scholar
• Immunex Corporation, Thousand Oaks, CA. Enbrel (etanercept): Product monograph; 2015 Oct 19 [accessed 2016 Oct 19]. https://www.amgen.ca/Enbrel_PM.pdf.
   Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337(3):141-7; PMID:9219699; http://dx.doi.org/10.1056/NEJM199707173370301
   PubMed Web of Science ®Google Scholar
• Langley RG, Gupta AK, Cherman AM, Inniss KA. Biologic therapeutics in the treatment of psoriasis. Part 1: review. J Cutan Med Surg 2007; 11(3):99-122.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54(7):2136-46; PMID:16802350; http://dx.doi.org/10.1002/art.21913
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130(2):323-33; quiz 591; PMID:16472588; http://dx.doi.org/10.1053/j.gastro.2005.11.030
   PubMed Web of Science ®Google Scholar
• Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, Ponsioen C, van Tuyl BA, Siersema PD, Fidder HH, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol 2013; 11(7):826-31; PMID:23376000; http://dx.doi.org/10.1016/j.cgh.2013.01.012
   PubMed Web of Science ®Google Scholar
• Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, Chen L, Xie F, Curtis JR, Lewis JD. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 2014; 12(5):811-7 e3; PMID:23811254; http://dx.doi.org/10.1016/j.cgh.2013.06.010
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004; 15(5):280-94; PMID:15370396; http://dx.doi.org/10.1080/09546630410017275
   PubMedGoogle Scholar
• Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol 2013; 9(10):949-58; PMID:24128157; http://dx.doi.org/10.1586/1744666X.2013.836060
   PubMed Web of Science ®Google Scholar
• Shukla R, Vender RB. Pharmacology of TNF inhibitors. TNF-alpha Inhibitors 2006:23-44; http://dx.doi.org/10.1007/3-7643-7438-1_3
   Google Scholar
• Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008; 20(4):431-5; PMID:18619538; http://dx.doi.org/10.1016/j.coi.2008.06.011
   PubMed Web of Science ®Google Scholar
• Lombardi G, Perego S, Sansoni V, Diani M, Banfi G, Altomare G. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. BMJ Open 2016; 6(12):e011941; PMID:27940624; http://dx.doi.org/10.1136/bmjopen-2016-011941
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131(2):308-16; PMID:19188093; http://dx.doi.org/10.1016/j.clim.2009.01.002
   PubMed Web of Science ®Google Scholar
• Schroter C, Gunther R, Rhiel L, Becker S, Toleikis L, Doerner A, Becker J, Schönemann A, Nasu D, Neuteboom B, et al. A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display. MAbs 2015; 7(1):138-51; PMID:25523975; http://dx.doi.org/10.4161/19420862.2014.985993
   PubMed Web of Science ®Google Scholar
• Ogura T, Tanaka Y, Toyoda H. Whole cell-based surface plasmon resonance measurement to assess binding of anti-TNF agents to transmembrane target. Anal Biochem 2016; 508:73-7; PMID:27349512; http://dx.doi.org/10.1016/j.ab.2016.06.021
   PubMed Web of Science ®Google Scholar
• Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001; 299(2):119-29; PMID:11730333; http://dx.doi.org/10.1006/abio.2001.5380
   PubMed Web of Science ®Google Scholar
• Kohno T, Tam LT, Stevens SR, Louie JS. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc 2007; 12(1):5-8; PMID:17502862;http://dx.doi.org/10.1038/sj.jidsymp.5650034
   PubMedGoogle Scholar
• Kim MS, Lee SH, Song MY, Yoo TH, Lee BK, Kim YS. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 2007; 374(5):1374-88; PMID:17996896; http://dx.doi.org/10.1016/j.jmb.2007.10.034
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301(2):418-26; PMID:11961039; http://dx.doi.org/10.1124/jpet.301.2.418
   PubMed Web of Science ®Google Scholar
• Demeule B, Shire SJ, Liu J. A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation. Anal Biochem 2009; 388(2):279-87; PMID:19289095; http://dx.doi.org/10.1016/j.ab.2009.03.012
   PubMed Web of Science ®Google Scholar
• Zhao H, Brautigam CA, Ghirlando R, Schuck P. Overview of current methods in sedimentation velocity and sedimentation equilibrium analytical ultracentrifugation. Curr Protoc Protein Sci 2013; Chapter 20: 20.12.1-20.12.49; Unit20 12; PMID:23377850; http://dx.doi.org/10.1002/0471140864.ps2012s71
   PubMedGoogle Scholar
• Chaton CT, Herr AB. Elucidating complicated assembling systems in biology using size-and-shape analysis of sedimentation velocity data. Methods Enzymol 2015; 562:187-204; PMID:26412652; http://dx.doi.org/10.1016/bs.mie.2015.04.004
   PubMed Web of Science ®Google Scholar
• Liu J, Yadav S, Andya J, Demeule B, Shire SJ. Analytical ultracentrifugation and its role in development and research of therapeutical proteins. Methods Enzymol 2015; 562:441-76; PMID:26412663; http://dx.doi.org/10.1016/bs.mie.2015.04.008
   PubMed Web of Science ®Google Scholar
• Krayukhina E, Uchiyama S. Analytical ultracentrifugation. In: Senda T, Maenaka K, eds. Advanced Methods in Structural Biology: Springer Japan, 2016:165-83; http://dx.doi.org/10.1007/978-4-431-56030-2_10
   Google Scholar
• Lebowitz J, Lewis MS, Schuck P. Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci 2002; 11(9):2067-79; PMID:12192063; http://dx.doi.org/10.1110/ps.0207702
   PubMed Web of Science ®Google Scholar
• Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 2007; 96(2):268-79; PMID:17080424; http://dx.doi.org/10.1002/jps.20760
   PubMed Web of Science ®Google Scholar
• Philo JS. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol 2009; 10(4):359-72; PMID:19519411; http://dx.doi.org/10.2174/138920109788488815
   PubMed Web of Science ®Google Scholar
• den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 2011; 28(4):920-33; PMID:20972611; http://dx.doi.org/10.1007/s11095-010-0297-1
   PubMed Web of Science ®Google Scholar
• MacGregor IK, Anderson AL, Laue TM. Fluorescence detection for the XLI analytical ultracentrifuge. Biophys Chem 2004; 108(1-3):165-85; PMID:15043928; http://dx.doi.org/10.1016/j.bpc.2003.10.018
   PubMed Web of Science ®Google Scholar
• Kingsbury JS, Laue TM. Fluorescence-detected sedimentation in dilute and highly concentrated solutions. Methods Enzymol 2011; 492:283-304; PMID:21333796; http://dx.doi.org/10.1016/B978-0-12-381268-1.00021-5
   PubMed Web of Science ®Google Scholar
• Zhao H, Mayer ML, Schuck P. Analysis of protein interactions with picomolar binding affinity by fluorescence-detected sedimentation velocity. Anal Chem 2014; 86(6):3181-7; PMID:24552356; http://dx.doi.org/10.1021/ac500093m
   PubMed Web of Science ®Google Scholar
• Nelson TG, Ramsay GD, Perugini MA. Fluorescence Detection System. In: Uchiyama S, Arisaka F, Stafford WF, Laue T, eds. Analytical Ultracentrifugation: Springer Japan, 2016:39-61; http://dx.doi.org/10.1007/978-4-431-55985-6_4
   Google Scholar
• Cole JW, Lary JW, Moody TP, Laue TM. Analytical ultracentrifugation: sedimentation velocity and sedimentation equilibrium. In: Correia JJ, Detrich H, eds. Methods Cell Biol. San Diego: Elsevier, 2008:143-79; PMID:17964931; http://dx.doi.org/10.1016/S0091-679X(07)84006-4
   Google Scholar
• Kroe RR, Laue TM. NUTS and BOLTS: applications of fluorescence-detected sedimentation. Anal Biochem 2009; 390(1):1-13; PMID:19103145; http://dx.doi.org/10.1016/j.ab.2008.11.033
   PubMed Web of Science ®Google Scholar
• Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J 2000; 78(3):1606-19; PMID:10692345; http://dx.doi.org/10.1016/S0006-3495(00)76713-0
   PubMed Web of Science ®Google Scholar
• Schuck P. Diffusion-deconvoluted sedimentation coefficient distributions for the analysis of interacting and non-interacting protein mixtures. In: Scott DJ, Harding SE, Rowe AJ, eds. Analytical Ultracentrifugation: Techniques and Methods. UK: RSC Publishing, 2005:26-49; http://dx.doi.org/10.1039/9781847552617-00026
   Google Scholar
• Eck MJ, Sprang SR. The structure of tumor necrosis factor-alpha at 2.6-a resolution - implications for receptor-binding. J Biol Chem 1989; 264(29):17595-605; PMID:2551905
   PubMed Web of Science ®Google Scholar
• Narhi LO, Philo JS, Li T, Zhang M, Samal B, Arakawa T. Induction of alpha-helix in the beta-sheet protein tumor necrosis factor-alpha: acid-induced denaturation. Biochemistry 1996; 35(35):11454-60; PMID:8784201; http://dx.doi.org/10.1021/bi952767n
   PubMed Web of Science ®Google Scholar
• Houel S, Hilliard M, Yu YQ, McLoughlin N, Martin SM, Rudd PM, Williams JP, Chen W. N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality. Analytical Chem 2014; 86(1):576-84; PMID:24308717; http://dx.doi.org/10.1021/ac402726h
   PubMed Web of Science ®Google Scholar
• Lyons DF, Lary JW, Husain B, Correia JJ, Cole JL. Are fluorescence-detected sedimentation velocity data reliable? Anal Biochem 2013; 437(2):133-7; PMID:23499970; http://dx.doi.org/10.1016/j.ab.2013.02.019
   PubMed Web of Science ®Google Scholar
• Krayukhina E, Uchiyama S, Fukui K. Effects of rotational speed on the hydrodynamic properties of pharmaceutical antibodies measured by analytical ultracentrifugation sedimentation velocity. Eur J Pharm Sci 2012; 47(2):367-74; PMID:22728396; http://dx.doi.org/10.1016/j.ejps.2012.06.005
   PubMed Web of Science ®Google Scholar
• Oda M, Uchiyama S, Robinson CV, Fukui K, Kobayashi Y, Azuma T. Regional and segmental flexibility of antibodies in interaction with antigens of different size. FEBS J 2006; 273(7):1476-87; PMID:16689933; http://dx.doi.org/10.1111/j.1742-4658.2006.05168.x
   PubMed Web of Science ®Google Scholar
• Oda M, Uchiyama S, Noda M, Nishi Y, Koga M, Mayanagi K, Azuma T. Effects of antibody affinity and antigen valence on molecular forms of immune complexes. Mol Immunol 2009; 47(2-3):357-64; PMID:19800690; http://dx.doi.org/10.1016/j.molimm.2009.09.009
   PubMed Web of Science ®Google Scholar
• Noda M, Uchiyama S, McKay AR, Morimoto A, Misawa S, Yoshida A, Shimahara H, Takinowaki H, Nakamura S, Kobayashi Y, et al. Assembly states of the nucleosome assembly protein 1 (NAP-1) revealed by sedimentation velocity and non-denaturing MS. Biochem J 2011; 436(1):101-12; PMID:21348863; http://dx.doi.org/10.1042/BJ20102063
   PubMed Web of Science ®Google Scholar
• Ishii K, Noda M, Yagi H, Thammaporn R, Seetaha S, Satoh T, Kato K, Uchiyama S. Disassembly of the self-assembled, double-ring structure of proteasome alpha7 homo-tetradecamer by alpha6. Sci Rep 2015; 5:18167; PMID:26657688; http://dx.doi.org/10.1038/srep18167
   PubMed Web of Science ®Google Scholar
• Kemmer G, Keller S. Nonlinear least-squares data fitting in Excel spreadsheets. Nat Protoc 2010; 5(2):267-81; PMID:20134427; http://dx.doi.org/10.1038/nprot.2009.182
   PubMed Web of Science ®Google Scholar
• Peters T. Metabolism: Albumin in the body. In: All about albumin: Biochemistry, genetics and medical applications. Academic Press, 1995; 188-250.
   Google Scholar
• Lamola AA, Russo M. Fluorescence excitation spectrum of bilirubin in blood: a model for the action spectrum for phototherapy of neonatal jaundice. Photochem Photobiol 2014; 90(2):294-6; PMID:23998276; http://dx.doi.org/10.1111/php.12167
   PubMed Web of Science ®Google Scholar
• Hill JJ, Laue TM. Protein Assembly in Serum and the Differences from Assembly in Buffer. Methods Enzymol 2015; 562:501-27; PMID:26412665; http://dx.doi.org/10.1016/bs.mie.2015.06.012
   PubMed Web of Science ®Google Scholar
• Schuck P, Perugini MA, Gonzales NR, Howlett GJ, Schubert D. Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys J 2002; 82(2):1096-111; PMID:11806949; http://dx.doi.org/10.1016/S0006-3495(02)75469-6
   PubMed Web of Science ®Google Scholar
• Laue T. Proximity energies: a framework for understanding concentrated solutions. J Mol Recognit 2012; 25(3):165-73; PMID:22407980; http://dx.doi.org/10.1002/jmr.2179
   PubMed Web of Science ®Google Scholar
• Tada M, Ishii-Watabe A, Suzuki T, Kawasaki N. Development of a cell-based assay measuring the activation of FcgammaRIIa for the characterization of therapeutic monoclonal antibodies. PLoS One 2014; 9(4):e95787; PMID:24752341; http://dx.doi.org/10.1371/journal.pone.0095787
   PubMedGoogle Scholar
• Banker MJ, Clark TH. Plasma/serum protein binding determinations. Curr Drug Metab 2008; 9(9):854-9; PMID:18991581; http://dx.doi.org/10.2174/138920008786485065
   PubMed Web of Science ®Google Scholar
• Howard ML, Hill JJ, Galluppi GR, McLean MA. Plasma protein binding in drug discovery and development. Comb Chem High Throughput Screen 2010; 13(2):170-87; PMID:20053162; http://dx.doi.org/10.2174/138620710790596745
   PubMed Web of Science ®Google Scholar
• Baker MA, Schneider EK, J XH, Cooper MA, Li J, Velkov T. The plasma protein binding proteome of ertapenem: A novel compound-centric proteomic approach for elucidating drug-plasma protein binding interactions. ACS Chem Biol 2016; 11(12):3353-64; PMID:27682196; http://dx.doi.org/10.1021/acschembio.6b00700
   Web of Science ®Google Scholar
• Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv 2015; 12(5):793-812; PMID:25518870; http://dx.doi.org/10.1517/17425247.2015.993313
   PubMed Web of Science ®Google Scholar
• Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the interaction between fcrn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol 2014; 5:682; PMID:25674083; http://dx.doi.org/10.3389/fimmu.2014.00682
   PubMed Web of Science ®Google Scholar
• Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL. The major histocompatibility complex–related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003; 197(3):315-22; PMID:12566415; http://dx.doi.org/10.1084/jem.20021829
   PubMed Web of Science ®Google Scholar
• Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view. J Biol Chem 2013; 288(38):27059-67; PMID:23943614; http://dx.doi.org/10.1074/jbc.M113.491530
   PubMed Web of Science ®Google Scholar
• Liang S, Dai J, Hou S, Su L, Zhang D, Guo H, Lou Z. Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab. J Biol Chem 2013; 288(19):13799-807; PMID:23504311; http://dx.doi.org/10.1074/jbc.M112.433961
   PubMed Web of Science ®Google Scholar
• Mukai Y, Nakamura T, Yoshikawa M, Yoshioka Y, Tsunoda S, Nakagawa S, Yamagata Y, Tsutsumi Y. Solution of the structure of the TNF-TNFR2 complex. Sci Signal 2010; 3(148):ra83; PMID:21081755; http://dx.doi.org/10.1126/scisignal.2000954
   PubMed Web of Science ®Google Scholar
• Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998; 16(16):421-32; PMID:9597136; http://dx.doi.org/10.1146/annurev.immunol.16.1.421
   PubMed Web of Science ®Google Scholar
• Krishna M, Nadler SG. Immunogenicity to biotherapeutics - the role of anti-drug immune complexes. Front Immunol 2016; 7:21; PMID:26870037; http://dx.doi.org/10.3389/fimmu.2016.00021
   PubMed Web of Science ®Google Scholar
• Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009; 45(2):124-31; PMID:19128982; http://dx.doi.org/10.1016/j.cyto.2008.11.008
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8(3):E501-7; PMID:17025268; http://dx.doi.org/10.1208/aapsj080359
   PubMed Web of Science ®Google Scholar
• Krayukhina E, Uchiyama S, Nojima K, Okada Y, Hamaguchi I, Fukui K. Aggregation analysis of pharmaceutical human immunoglobulin preparations using size-exclusion chromatography and analytical ultracentrifugation sedimentation velocity. J Biosci Bioeng 2013; 115(1):104-10; PMID:22925901; http://dx.doi.org/10.1016/j.jbiosc.2012.07.021
   PubMed Web of Science ®Google Scholar
• Jefferis R. Posttranslational modifications and the immunogenicity of biotherapeutics. J Immunol Res 2016; 2016:5358272; PMID:27191002; http://dx.doi.org/10.1155/2016/5358272
   PubMed Web of Science ®Google Scholar
• Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, Topp EM. Immunogenicity of therapeutic protein aggregates. J Pharm Sci 2016; 105(2):417-30; PMID:26869409; http://dx.doi.org/10.1016/j.xphs.2015.11.002
   PubMed Web of Science ®Google Scholar
• Brautigam CA. Calculations and publication-quality illustrations for analytical ultracentrifugation data. Methods Enzymol 2015; 562:109-33; PMID:26412649; http://dx.doi.org/10.1016/bs.mie.2015.05.001
   PubMed Web of Science ®Google Scholar
• Keller S, Vargas C, Zhao H, Piszczek G, Brautigam CA, Schuck P. High-precision isothermal titration calorimetry with automated peak-shape analysis. Anal Chem 2012; 84(11):5066-73; PMID:22530732; http://dx.doi.org/10.1021/ac3007522
   PubMed Web of Science ®Google Scholar